Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGRX-1942 in Advanced Solid Tumors and Hematologic Malignancies
NCT06484816Phase 1Recruiting
- Sponsor
- Shenzhen TargetRx
- Start
- Jul 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TGRX-1942 in solid tumor (advanced stage), hematologic malignancy and non-small cell lung cancer (NSCLC), sponsored by Shenzhen TargetRx. Primary endpoints: Adverse events/serious adverse events and Maximum Tolerated Dose. Started Jul 2024; status: recruiting.
02
Drugs
TGRX-1942
03
Conditions
solid tumor (advanced stage)hematologic malignancynon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06484816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484816.